中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 5
May  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(5): 1165-1168

Effect of different antiviral drugs in reducing the risk of hepatitis B virus-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.05.040

  • Department of Infectious Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China

Research funding:

Guangdong Basic and Applied Basic Research Foundation (2021A1515011589);

Clinical Research Project of Affiliated Hospital of Guangdong Medical University (LCYJ2020B001)

More Information
  • Corresponding author: ZHENG Weiqiang, zwqgd@sina.com(ORCID: 0000-0002-6979-2283); HAN Huanqin, huanqinhan@126.com(ORCID: 0000-0002-2333-1561)
  • Received Date: 2021-11-03
  • Published Date: 2022-05-20
    Abstract
  • Antiviral therapy can reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. As for the first-line antiviral drugs, more studies have shown that tenofovir disoproxil fumarate may be better than entecavir in reducing the risk of HCC, especially among Asian patients; a limited number of studies have shown that tenofovir alafenamide fumarate may be better than tenofovir disoproxil fumarate in reducing the risk of HCC; interferon has a better effect than nucleos(t)ide analogues alone in reducing the risk of HCC. Among the currently available drugs, interferon combined with nucleos(t)ide analogues may be the best choice to reduce the risk of HCC in patients at a high risk of HCC. The level of evidence-based medicine is weak for comparing the effect of different drugs in reducing the risk of HCC, and randomized controlled trials are needed for further clarification. In practice, it is necessary to weigh the risk of HCC, drug tolerance and economic affordability based on the patient's basic conditions and actual situations, so as to develop individualized anti-viral strategies.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [2]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007.
    [3]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [4]
    SETO WK, LO YR, PAWLOTSKY JM, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392(10161): 2313-2324. DOI: 10.1016/S0140-6736(18)31865-8.
    [5]
    WANG X, LIU X, DANG Z, et al. Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis[J]. Gut Liver, 2020, 14(2): 232-247. DOI: 10.5009/gnl18546.
    [6]
    CHOI WM, YIP TC, LIM YS, et al. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments[J]. J Hepatol, 2022, 76(1): 186-194. DOI: 10.1016/j.jhep.2021.09.017.
    [7]
    LIAW YF, SUNG JJ, CHOW WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531. DOI: 10.1056/NEJMoa033364.
    [8]
    HOSAKA T, SUZUKI F, KOBAYASHI M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J]. Hepatology, 2013, 58(1): 98-107. DOI: 10.1002/hep.26180.
    [9]
    BONILLA GUERRERO R, ROBERTS LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma[J]. J Hepatol, 2005, 42(5): 760-777. DOI: 10.1016/j.jhep.2005.02.005.
    [10]
    PAPATHEODORIDIS GV, IDILMAN R, DALEKOS GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology, 2017, 66(5): 1444-1453. DOI: 10.1002/hep.29320.
    [11]
    KIM WR, LOOMBA R, BERG T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Cancer, 2015, 121(20): 3631-3638. DOI: 10.1002/cncr.29537.
    [12]
    CHOI J, KIM HJ, LEE J, et al. Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B: A Korean Nationwide Cohort Study[J]. JAMA Oncol, 2019, 5(1): 30-36. DOI: 10.1001/jamaoncol.2018.4070.
    [13]
    ZHANG H, ZENG W. Lower risk of hepatocellular carcinoma with Tenofovir vs Entecavir in patients with chronic hepatitis B[J]. JAMA Oncol, 2019, 5(6): 914-915. DOI: 10.1001/jamaoncol.2019.0641.
    [14]
    CHOI J, KO MJ, LIM YS. Lower risk of hepatocellular carcinoma with Tenofovir vs Entecavir in patients with chronic hepatitis B-in reply[J]. JAMA Oncol, 2019, 5(6): 916-917. DOI: 10.1001/jamaoncol.2019.0650.
    [15]
    KIM SU, SEO YS, LEE HA, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea[J]. J Hepatol, 2019, 71(3): 456-464. DOI: 10.1016/j.jhep.2019.03.028.
    [16]
    LEE SW, KWON JH, LEE HL, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: A large-scale, propensity score analysis[J]. Gut, 2020, 69(7): 1301-1308. DOI: 10.1136/gutjnl-2019-318947.
    [17]
    PAPATHEODORIDIS GV, DALEKOS GN, IDILMAN R, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020, 73(5): 1037-1045. DOI: 10.1016/j.jhep.2020.06.011.
    [18]
    TSENG CH, HSU YC, CHEN TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(12): 1039-1052. DOI: 10.1016/S2468-1253(20)30249-1.
    [19]
    CHOI WM, CHOI J, LIM YS. Effects of Tenofovir vs Entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2021, 19(2): 246-258. e9. DOI: 10.1016/j.cgh.2020.05.008.
    [20]
    DAVE S, PARK S, MURAD MH, et al. Comparative effectiveness of Entecavir versus Tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta-analysis[J]. Hepatology, 2021, 73(1): 68-78. DOI: 10.1002/hep.31267.
    [21]
    GU L, YAO Q, SHEN Z, et al. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2020, 35(9): 1467-1476. DOI: 10.1111/jgh.15036.
    [22]
    LI M, LV T, WU S, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: A critical systematic review and meta-analysis[J]. Hepatol Int, 2020, 14(1): 105-114. DOI: 10.1007/s12072-019-10005-0.
    [23]
    YIP TC, WONG VW, CHAN HL, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than Entecavir in patients with chronic HBV infection in China[J]. Gastroenterology, 2020, 158(1): 215-225. e6. DOI: 10.1053/j.gastro.2019.09.025.
    [24]
    LIU H, SHI Y, HAYDEN JC, et al. Tenofovir treatment has lower risk of hepatocellular carcinoma than Entecavir treatment in patients with chronic hepatitis B: A systematic review and meta-analysis[J]. Liver Cancer, 2020, 9(4): 468-476. DOI: 10.1159/000507253.
    [25]
    ZHANG Z, ZHOU Y, YANG J, et al. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: A meta analysis[J]. BMC Cancer, 2019, 19(1): 511. DOI: 10.1186/s12885-019-5735-9.
    [26]
    VIGANÒ M, LOGLIO A, GROSSI G, et al. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?[J]. Expert Rev Anti Infect Ther, 2018, 16(2): 153-161. DOI: 10.1080/14787210.2018.1428561.
    [27]
    CHAN HLY, LIM YS, SETO WK. Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)[J]. Gut, 2020, 69(Suppl 2): A1-A95. DOI: org/ 10.1136/gutjnl-2020-IDDF.144.
    [28]
    LEE HW, CHO YY, LEE H, et al. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B[J]. J Viral Hepat, 2021, 28(11): 1570-1578. DOI: 10.1111/jvh.13601.
    [29]
    YIP TC, WONG GL, CHAN HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3): 361-370. DOI: 10.1016/j.jhep.2018.10.014.
    [30]
    CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195. DOI: 10.1016/S2468-1253(16)30024-3.
    [31]
    REN H, HUANG Y. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B[J]. J Viral Hepat, 2019, 26(Suppl 1): 5-31. DOI: 10.1111/jvh.13150.
    [32]
    Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: A 2021 update[J]. J Clin Hepatol, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.

    中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J]. 临床肝胆病杂志, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.
    [33]
    BRUNETTO MR, BONINO F. Interferon therapy of chronic hepatitis B[J]. Intervirology, 2014, 57(3-4): 163-170. DOI: 10.1159/000360941.
    [34]
    LEE SK, KWON JH, LEE SW, et al. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B[J]. Liver Int, 2021, 41(2): 288-294. DOI: 10.1111/liv.14701.
    [35]
    REN P, CAO Z, MO R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk[J]. Expert Opin Biol Ther, 2018, 18(10): 1085-1094. DOI: 10.1080/14712598.2018.1518423.
    [36]
    YANG S, LIN Q, LIN W, et al. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: A systematic review[J]. World J Surg Oncol, 2016, 14(1): 159. DOI: 10.1186/s12957-016-0912-7.
    [37]
    LIANG KH, HSU CW, CHANG ML, et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B[J]. J Infect Dis, 2016, 213(6): 966-974. DOI: 10.1093/infdis/jiv547.
    [38]
    MAO QG, LIANG HQ, YIN YL, et al. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B[J]. Clin Res Hepatol Gastroenterol, 2021, 46(1): 101758. DOI: 10.1016/j.clinre.2021.101758.
    [39]
    LI SY, LI H, XIONG YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study[J]. J Viral Hepat, 2017, 24(Suppl 1): 12-20. DOI: 10.1111/jvh.12755.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (545) PDF downloads(76) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return